Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
Internal Medicine (Tokyo, Japan)|April 2, 2023
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical PracticeShun Tsuchiya, Tomoiku Takaku, Naoki Watanabe, et al.
American Journal of Hematology|February 5, 2024
Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remissionSatoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, et al.
Leukemia & Lymphoma|September 22, 2015
Clinical significance of co-expression of MYC and BCL2 protein in aggressive B-cell lymphomas treated with a second line immunochemotherapyKatsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, et al.
Annals of Hematology|January 21, 2014
Normal karyotype acute myeloid leukemia with the CD7+ CD15+ CD34+ HLA-DR + immunophenotype is a clinically distinct entity with a favorable outcomeNoriyoshi Iriyama, Norio Asou, Yasushi Miyazaki, et al.
International Journal of Hematology|March 18, 2015
Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphomaDaisuke Kurita, Katsuhiro Miura, Masaru Nakagawa, et al.
Leukemia & Lymphoma|April 14, 2016
Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapyHiromichi Takahashi, Katsuhiro Miura, Masaru Nakagawa, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 7, 2025
Adverse events during preoperative autologous blood donation and its usage in obstetrical patients: A multicenter, retrospective survey in JapanAkihiko Yokohama, Hiroshi Fujita, Kazuhiro Nagai, et al.
Blood Advances|February 8, 2024
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysisTakashi Toya, Kota Mizuno, Masatoshi Sakurai, et al.
Annals of Hematology|April 26, 2018
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALLYoshihiro Hatta, Shuichi Mizuta, Keitaro Matsuo, et al.
Oncology Reports|November 21, 2012
Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomasNoriyoshi Iriyama, Hiromichi Takahashi, Yoshihiro Hatta, et al.
Pageof 13